To interrogate the efficacy of HIF1α/HDAC1/EZH2 inhibitors in vivo, we used the immune-competent syngeneic 4T1 murine breast tumor model that closely mimics human TNBC breast cancer tumorigenesis28. The gene discussed is HIF1A; the disease is breast carcinoma.